Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
240 hedge funds and large institutions have $8.73B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 84 increasing their positions, 97 reducing their positions, and 116 closing their positions.
125% more call options, than puts
Call options by funds: $596M | Put options by funds: $265M
7% more funds holding in top 10
Funds holding in top 10: 30 → 32 (+2)
3% less capital invested
Capital invested by funds: $8.96B → $8.73B (-$230M)
13% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 97
27% less funds holding
Funds holding: 329 → 240 (-89)
75% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 116
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$404M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$273M |
| 3 |
JP Morgan Chase
New York
|
+$173M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$151M |
| 5 |
SFM
Soros Fund Management
New York
|
+$151M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$283M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$267M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$181M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$165M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$108M |
BHVN Hedge Fund Activity: Q3 2022 in Review
240 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2022, worth a combined $8.73B — down 2.6% from $8.96B a quarter earlier.
Sellers outnumbered buyers: 116 funds closed out of BHVN and 29 opened new positions — a net loss of 87 holders — while 97 trimmed existing stakes and 84 added.
The largest buyer was HBK Investments, adding an estimated $404M. The largest seller was Marshall Wace, cutting an estimated $283M.
- 240 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2022, down from 329 in Q2 2022.
- Funds reported $8.73B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2022, down 2.6% quarter-over-quarter.
- 29 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2022 and 116 closed out, a net change of -87 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2022 was HBK Investments, an estimated $404M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2022 was Marshall Wace, an estimated $283M sold.
Based on aggregated 13F filings for Q3 2022.